Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs

@inproceedings{Rigby2017ReviewOR,
  title={Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs},
  author={William F C Rigby and Kathy Lampl and Jason M. Low and Daniel E. Furst},
  booktitle={International journal of rheumatology},
  year={2017}
}
Safety concerns associated with many drugs indicated for the treatment of rheumatoid arthritis (RA) can be attenuated by the early identification of toxicity through routine laboratory monitoring; however, a comprehensive review of the recommended monitoring guidelines for the different available RA therapies is currently unavailable. The aim of this review is to summarize the current guidelines for laboratory monitoring in patients with RA and to provide an overview of the laboratory… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 158 REFERENCES

L

D. Liu, A. Ahmet
  • Ward et al., “A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy,”Allergy, Asthma&Clinical Immunology, vol. 9, article 30
  • 2013
VIEW 13 EXCERPTS
HIGHLY INFLUENTIAL

T

M. Dougados, K. Kissel
  • Sheeran et al., “Adding tocilizumab or switching to tocilizumabmonotherapy inmethotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY),”Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 43–50
  • 2013
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

B

J. H. Salmon, P. Cacoub
  • Combe et al., “Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry,” RMD Open, vol. 1, article e000034, no. 1
  • 2015
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

M

G. Kerekes, M. T. Nurmohamed
  • A. González-Gay et al., “Rheumatoid arthritis and metabolic syndrome,” Nature Reviews Rheumatology, vol. 10, no. 11, pp. 691–696
  • 2014
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

J

M. C. Genovese, A. Rubbert-Roth
  • S. Smolen et al., “Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: A cumulative analysis of up to 4.6 years of exposure,” The Journal of Rheumatology, vol. 40, no. 6, pp. 768–780
  • 2013
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

D

M. J. Peters, D. P. Symmons
  • McCarey et al., “EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis,” Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 325–331
  • 2010
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

H

Y.-B. Park
  • K. Choi, M.-Y. Kim et al., “Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: A prospective study,” American Journal of Medicine, vol. 113, no. 3, pp. 188–193
  • 2002
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

I

C. Charles-Schoeman, M. A. Gonzalez-Gay
  • Kaplan et al., “Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist,” Seminars in Arthritis and Rheumatism, vol. 46, no. 1, pp. 71–80
  • 2016
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

K

D. A. Pappas, G. W. Reed
  • Saunders et al., “Characteristics associated with biologic monotherapy use in biologic-naive patients with rheumatoid arthritis in a US registry population,” Rheumatology andTherapy, vol. 2, no. 1, pp. 85–95
  • 2015
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…